Back to overview

Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Vicari Alain P., Schoepfer Alain M., Meresse Bertrand, Goffin Laurence, Léger Olivier, Josserand Soheila, Guégan Nicolas, Yousefi Shida, Straumann Alex, Cerf-Bensussan Nadine, Simon Hans-Uwe, Chvatchko Yolande,
Project Defining clinically meaningful therapeutic endpoints in Eosinophilic Esophagitis
Show all

Original article (peer-reviewed)

Journal mAbs
Volume (Issue) 9(6)
Page(s) 927 - 944
Title of proceedings mAbs
DOI 10.1080/19420862.2017.1332553


Interleukin-15 (IL-15) is a critical regulator of immune responses, especially at mucosal interfaces within the gastro-intestinal tract. Here, we describe the discovery and characterization of a humanized antibody to IL-15. Data from its epitope and mode of action, cell biology and primate pharmacology, as well as translational studies in human samples and in vivo proof-of-concept experiments in mouse models demonstrate the therapeutic potential of this new antibody targeting IL-15 for refractory celiac disease and eosinophilic esophagitis.